Azd0530 (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 272 | 進行性骨化性線維異形成症 | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04307953 (ClinicalTrials.gov) | August 5, 2020 | 11/3/2020 | Saracatinib Trial TO Prevent FOP | Saracatinib Trial TO Prevent FOP | Fibrodysplasia Ossificans Progressiva | Drug: AZD0530 Difumarate;Drug: Matching placebo | VU University Medical Center | Royal National Orthopaedic Hospital NHS Trust;Klinikum Garmisch-Patenkirchen;University of Oxford;Brigham and Women's Hospital;AstraZeneca;Innovative Medicines Initiative | Recruiting | 18 Years | 65 Years | All | 20 | Phase 2 | Germany;Netherlands;United Kingdom |
| 2 | EUCTR2019-003324-20-NL (EUCTR) | 08/01/2020 | 16/10/2019 | A clinical trial to judge the safety, tolerability and effects on abnormal bone formation of reseach medication AZD 0530 (sarcatinib) in patients with FOP | Saracatinib trial TO Prevent FOP - STOPFOP | Fibrodyplasia Ossificans Progressiva (FOP) MedDRA version: 20.0;Level: PT;Classification code 10068715;Term: Fibrodysplasia ossificans progressiva;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: Saracatinib Product Code: AZD0530 INN or Proposed INN: Saracatinib Other descriptive name: SARACATINIB DIFUMARATE | VU University Medical Center | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 16 | Phase 2 | Netherlands |